FDAnews
www.fdanews.com/articles/101837-arana-begins-phase-ii-trials-for-art621

Arana Begins Phase II Trials for ART621

December 5, 2007

Australian biotechnology company Arana Therapeutics will begin a three-month Phase IIa study of ART621 in psoriasis patients and a Phase II study in rheumatoid arthritis.

The psoriasis study is expected to start in the first quarter of 2008 and the rheumatoid arthritis program is planned for the third quarter.   

Arana also has completed pharmacokinetic analysis from the Phase I trial of ART621. The data indicate ART621 has a half-life of approximately 14 days, suggesting that despite its smaller size, ART621 remains in the blood stream for at least as long as other anti-tumor necrosis factor antibody products, Arana said.